7543-20-6

Basic information

• Product Name: Ethanone, 1-phenyl-2-(4-quinolinyl)-
• CAS NO: 7543-20-6
• Molecular Formula: C17H13NO
• Molecular Weight: 247.296
• Mol File: 7543-20-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Ethanone, 1-phenyl-2-(4-quinolinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-phenyl-2-(4-quinolinyl)-(7543-20-6)
• EPA Substance Registry System: Ethanone, 1-phenyl-2-(4-quinolinyl)-(7543-20-6)

Safety Data

• Hazardous Substances Data: 7543-20-6(Hazardous Substances Data)

Usage

General Description

Ethanone, 1-phenyl-2-(4-quinolinyl)- is a chemical compound with the molecular formula C18H13NO. It is a ketone derivative with a phenyl group and a 4-quinolinyl group attached to the carbon atoms. Ethanone, 1-phenyl-2-(4-quinolinyl)- is also known as 4-acetylphenylquinoline and is commonly used in organic synthesis and pharmaceutical research. It has been reported to possess potential biological activities, including anti-inflammatory, anti-cancer, and antimicrobial properties. Additionally, it has been investigated for its potential use in the development of new drugs and pharmaceutical applications.

Upstream product

• 70437-06-8 1-phenyl-2-(4-quinolyl)acetylene 
• 93-89-0 benzoic acid ethyl ester 
• 138-89-6 p-dimethylaminonitrosobenzene 
• 98-86-2 acetophenone 
• 113999-77-2 2-[1-(4-chloro-benzyl)-1H-[4]chinolyLiDene]-1-phenyl-ethanone 
• 112440-93-4 2-[1-(2,4-dichloro-benzyl)-1H-[4]chinolyLiDene]-1-phenyl-ethanone 
• 491-35-0 C₆H₄NCH₂CHCCH₂ 
• 93-58-3 benzoic acid methyl ester 

Relevant articles and documents

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

Pyrazole-based inhibitors of the transforming growth factor-β type I receptor kinase domain (TβR-I) are described. Examination of the SAR in both enzyme- and cell-based in vitro assays resulted in the emergence of two subseries featuring differing selectivity versus p38 MAP kinase. A common binding mode at the active site has been established by successful cocrystallization and X-ray analysis of potent inhibitors with the TβR-I receptor kinase domain.

Studies on quinoline and isoquinoline derivatives. VIII. Hydration and hydrogenation of ethynyl substituents attached to the pyridine moiety of quinoline and isoquinoline rings

-